Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.